複雑性尿路感染症を対象としたCefmenoxime(SCE-1365)の臨床的検討 (Cefmenoxime(CMX,SCE-1365)<特集>)

概要

論文の詳細を見る
Fundamental and clinical studies were made on cefmenoxime (CMX, SCE-1365) in 38 cases of complicated urinary tract infections, and the following conclusions were obtained: 1) Antibacterial activity In the test of MICs of cefazolin, cefotiam and cefmenoxime against 14 strains of Serratia. marcescens, the most frequent clinical isolates from the trial cases, all of the strains were resistant to cefazolin and cefotiam, when the inoculum size was 106CFU/ml. On the other hand, cefmenoxime showed a wide sensitivity distribution with a peak at 12.5μg/ml. 2) Clinical studies In 33 cases treated by intravenous drip instillation of 2 g of cefmenoxime per day, cefmenoxime's effect was excellent in 6 cases, moderate in 16 cases, and poor in 11 cases; the effectiveness rate was 66.7%. In 5 cases treated by intramuscular injection of fg of cefmenoxime per day, its effect was excellent in 1 case, moderate in 2 cases, and poor in 2 cases; the effectiveness rate was 60%. Any noteworthy side effects were not observed.
公益社団法人日本化学療法学会の論文